Peijia Medical-B (09996): The State Drug Administration accepted the registration application for TaurusNxT® “non-formaldehyde crosslinked” dry valve transcatheter aortic valve replacement system

Zhitong Finance App News, Peijia Medical-B (09996) issued an announcement. Recently, the company received an acceptance notice from the State Drug Administration of the People's Republic of China confirming acceptance of the registration application for the TaurusNxT® “non-formaldehyde crosslinked” dry valve transcatheter aortic valve replacement (“TAVR”) system.

TaurusNXT® is a third-generation TAVR system developed in-house. It uses patented non-formaldehyde biological tissue crosslinking technology to eliminate the root cause of valve calcification, which is the main cause of valve degradation. This technology aims to improve the durability and biocompatibility of artificial aortic valves. Furthermore, compared to traditional tissue drying technology using glycerol, the system uses ultra-low temperature vacuum freeze-drying technology. This method helps maintain the physical integrity of valve tissue, and can also pre-install an artificial aortic valve onto the conveyor. The TaurusNXT® conveyor has also been upgraded to have recyclable and adjustable bending characteristics, helping doctors to more easily guide the artificial aortic valve to the target implant position, thereby further improving the safety of surgery.

The system has been accepted by the State Drug Administration's special approval procedure for innovative medical devices, and priority evaluation and approval will be given in the future.